Skip to main content

Advertisement

SpringerLink
Log in

Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients

  • Research Article
  • Published:
Tumor Biology

An Erratum to this article was published on 30 September 2016

Abstract

Accurate evaluation of human epidermal growth factor receptor 2 (HER2) status is quite crucial for invasive breast tumor patients in order to select anti-HER2 therapy for effective clinical outcomes. Immunohistochemistry (IHC) assay is routinely used to evaluate the HER2 oncoprotein overexpression but is unable to explain the chromosomal and genetic alterations and has been considered as a hot issue in IHC-equivocal cases. We investigated these molecular aberrations in correlation with prognostic factors. A cohort of 154 IHC-equivocal (+2) cases was selected and retrospectively analyzed by dual-probe fluorescence in situ hybridization (FISH) assay by using locus-specific HER2 and centromere enumeration probes (CEP17) for the identification of HER2 proto-oncogene amplification and chromosomal copy number per cell, respectively. The data were analyzed by SPSS 16.0 version using chi-square test (p < 0.05). We identified 36 out of 154 cases (23.4 %) showing HER2 gene amplification (average HER2 gene copies per cell >4 or <4 with HER2/CEP17 ratio >2) in concordance with HER2 oncoprotein overexpression, and significant correlation was observed with prognostic parameters including histological type, tumor grade II to III, histology and pathological type, lymphatic invasion, ductal carcinoma in situ (DCIS), and estrogen-positive and progesterone-negative receptors. Of the 154 cases, 18 cases (11.7 %) showed polysomy 17 with CEP17 probe signals per cell ≥3 and 22 cases (14.3 %) presented monosomy 17 (CEP17 probe signals per cell ≤1). Our data indicate that the use of anti-HER2 therapy should not be suggested unless true evaluation of HER2 protein expression is made regarding gene amplification essentially in IHC-ambiguous invasive breast tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Annual-Cancer-Registry-Report. Lahore: Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, (CRCDM) CRaCDM;2012.

  2. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9):1046–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Montemurro F, Cosimo SD, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013;24:2715–24.

    Article  CAS  PubMed  Google Scholar 

  4. Han X, Shi Y, Ma L, Lyu Z, Yang H, Yao J, et al. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients. Chin Med J Engl. 2014;127(2):246–53.

    CAS  PubMed  Google Scholar 

  5. Dang HZ, Yu Y, Jiao SC. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. World J Gastroenterol. 2012;18(19):2402–7.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.

    Article  CAS  PubMed  Google Scholar 

  7. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34(6):791–808.

    Article  CAS  PubMed  Google Scholar 

  8. Takashima T, Nakayama T, Yoshidome K, Kawajiri H, Kamigaki S, Tsurutani J, et al. Phase II Study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. Anticancer Res. 2014;34:3583–8.

    CAS  PubMed  Google Scholar 

  9. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157–63.

    Article  CAS  PubMed  Google Scholar 

  10. Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist. 2006;11 Suppl 1:34–41.

    Article  CAS  PubMed  Google Scholar 

  11. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–26.

    Article  CAS  PubMed  Google Scholar 

  12. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.

    Article  PubMed  Google Scholar 

  13. Orsaria M, Khelifa S, Buza N, Kamath A, Hui P. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification. J Clin Pathol. 2013;66(12):1070–5.

    Article  PubMed  Google Scholar 

  14. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol. 2000;13(11):1238–43.

    Article  CAS  PubMed  Google Scholar 

  15. Panjwani P, Epari S, Karpate A, Shirsat H, Rajsekharan P, Basak R, et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization and immunohistochemistry: experience of a tertiary cancer referral centre in India. Indian J Med Res. 2010;132:287–94.

    CAS  PubMed  Google Scholar 

  16. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the north central cancer treatment group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24(19):3032–8.

    Article  PubMed  Google Scholar 

  17. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.

    Article  CAS  PubMed  Google Scholar 

  18. Goud KI, Dayakar S, Vijayalaxmi K, Babu SJ, Reddy PV. Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. Indian J Med Res. 2012;135:312–7.

    PubMed  PubMed Central  Google Scholar 

  19. Wang S, Hossein Saboorian M, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15(2):137–45.

    Article  PubMed  Google Scholar 

  20. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19(10):2714–21.

    Article  CAS  PubMed  Google Scholar 

  21. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18(21):3651–64.

    Article  CAS  PubMed  Google Scholar 

  22. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol. 2005;16(11):1755–61.

    Article  CAS  PubMed  Google Scholar 

  23. Prati R, Apple SK, He J, Gornbein JA, Chang HR. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J. 2005;11(6):433–9.

    Article  CAS  PubMed  Google Scholar 

  24. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006;13 Suppl 1:S15–24.

    Article  CAS  PubMed  Google Scholar 

  25. Crowe JP, Patrick RJ, Rybicki LA, Escobar PF, Weng D, Thomas Budd G, et al. A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. Breast. 2006;15(6):728–35.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Quaid-i-Azam University, Islamabad, 45320, Pakistan

    Muhammad Afzal, Muhammad Sikander Hussain, Muhammad Naveed Aziz, Iram Murtaza, Mariam Anees & Aneesa Sultan

  2. Shifa International Hospital, H-8/4, Islamabad, Pakistan

    Muhammad Afzal & Mohammed Amir

  3. Atta-ur-Rehman School of Applied BioSciences (ASAB), National University of Science and Technology (NUST), Islamabad, Pakistan

    Muhammad Jawad Hassan & Sheeba Murad

Authors
  1. Muhammad Afzal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammed Amir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Muhammad Jawad Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muhammad Sikander Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muhammad Naveed Aziz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sheeba Murad
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Iram Murtaza
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mariam Anees
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Aneesa Sultan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aneesa Sultan.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s13277-016-5419-x.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afzal, M., Amir, M., Hassan, M.J. et al. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients. Tumor Biol. 37, 8665–8672 (2016). https://doi.org/10.1007/s13277-015-4657-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4657-7

Keywords

Search

Navigation